Aidan Yuan Jie Low
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aidan Yuan Jie Low has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aldo J. Montano-Loza
Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Alberta, Canada
2 shared publications - Corrine Lee Singh
Yong Loo Lin School of Medicine, National University of Singapore, Singapore
2 shared publications - Ellina Lytvyak
Department of Medicine, University of Alberta, Edmonton, AB, Canada
2 shared publications - Jarell Jie-Rae Tan
Yong Loo Lin School of Medicine, National University of Singapore, Singapore
2 shared publications - Shi Jie Ong
Yong Loo Lin School of Medicine, National University of Singapore, Singapore
2 shared publications - Yu Jun Wong
Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore
2 shared publications
Latest Publications
- Open Access
- 8 May 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (6)
Symptom burden and treatment patterns in primary biliary cholangitis: A systematic review and meta-analysis
Background: Patients with primary biliary cholangitis (PBC) often suffer from debilitating symptoms, yet the overall symptom burden has not been systematically quantified. This study aims to systematically review the prevalence and severity of the symptom burden in PBC patients. Methods: We conducted a systematic search of 3 electronic databases to include studies that reported the prevalence and severity of PBC symptoms. Subgroup analyses were performed based on study type, publication year, risk of bias, study location, sex, and latitude. Results: A total of 25 studies involving 13,178 patients were included. Fatigue was the most common symptom, affecting 51% of patients, followed by pruritus at 33%. Severe fatigue and severe pruritus were reported in 23% and 10% of patients, respectively. The prevalence of fatigue was significantly higher in more recent studies, those with smaller sample sizes, and studies published as abstracts. Fatigue score was significantly higher in female patients compared with males. Severe fatigue was more prevalent in studies conducted in North America/Europe than those from Asia (26% vs. 8%, p =0.0005), and in studies with a higher proportion of patients with cirrhosis (28% vs. 8%, p =0.0005). Despite the high burden, only 36% of PBC patients with pruritus received anti-pruritic treatment, with antihistamines being the most frequently prescribed medication. Conclusions: Over half of PBC patients experience significant symptom burden, with substantial ethnic disparities identified. The proportion and quality of appropriate symptom management in PBC are suboptimal. There remains an unmet need for standardized assessment, consistent reporting, and improved management strategies for PBC-related symptoms in future research.
- 8 May 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (6)
Open AccessSymptom burden and treatment patterns in primary biliary cholangitis: A systematic review and meta-analysis
Background: Patients with primary biliary cholangitis (PBC) often suffer from debilitating symptoms, yet the overall symptom burden has not been systematically quantified. This study aims to systematically review the prevalence and severity of the symptom burden in PBC patients. Methods: We conducted a systematic search of 3 electronic databases to include studies that reported the prevalence and severity of PBC symptoms. Subgroup analyses were performed based on study type, publication year, risk of bias, study location, sex, and latitude. Results: A total of 25 studies involving 13,178 patients were included. Fatigue was the most common symptom, affecting 51% of patients, followed by pruritus at 33%. Severe fatigue and severe pruritus were reported in 23% and 10% of patients, respectively. The prevalence of fatigue was significantly higher in more recent studies, those with smaller sample sizes, and studies published as abstracts. Fatigue score was significantly higher in female patients compared with males. Severe fatigue was more prevalent in studies conducted in North America/Europe than those from Asia (26% vs. 8%, p =0.0005), and in studies with a higher proportion of patients with cirrhosis (28% vs. 8%, p =0.0005). Despite the high burden, only 36% of PBC patients with pruritus received anti-pruritic treatment, with antihistamines being the most frequently prescribed medication. Conclusions: Over half of PBC patients experience significant symptom burden, with substantial ethnic disparities identified. The proportion and quality of appropriate symptom management in PBC are suboptimal. There remains an unmet need for standardized assessment, consistent reporting, and improved management strategies for PBC-related symptoms in future research.
- Open Access
- 24 April 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (5)
Prevalence and clinical impact of hepatic steatosis on autoimmune liver disease: A systematic review and meta-analysis
Background: The clinical impact of hepatic steatosis (HS) among patients with autoimmune liver disease (AILD) remains unclear. We aim to determine the prevalence of HS and its clinical impact on treatment response and outcomes in patients with AILD. Methods: We systematically searched 3 electronic databases until 17 December 2025, including all studies that reported the prevalence, clinical impact, and treatment response of AILD patients with concomitant HS. The temporal trend of HS prevalence was analyzed using a quasi-Poisson regression model, with annual percent changes (APC, %) calculated. Results: Overall, 44 studies, comprising 19,898 patients with autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) were included. The pooled prevalence of HS in patients with AIH, PBC, and PSC was 27.3%, 32.9%, and 21.6%, respectively. HS prevalence has significantly increased among PBC patients since 2010 (APC: +37.4%). While concomitant HS was associated with a higher risk of hepatic decompensation (OR: 1.6, 95% CI: 1.3–2.1, I 2 =0%) and hepatocellular carcinoma (OR: 1.8, 95% CI: 1.3–2.6, I 2 =0%) in patients with AIH, HS did not influence the clinical outcomes in patients with PBC. Treatment response in AIH and PBC was not influenced by concomitant HS. Available data on PSC with concomitant HS were insufficient to assess its association with clinical outcomes. Conclusions: AIH patients with concomitant HS had worse outcomes than those without HS; whereas HS did not influence the clinical outcomes in patients with PBC. Future research evaluating the impact of HS on PSC and overlap syndrome is much needed.
- 24 April 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (5)
Open AccessPrevalence and clinical impact of hepatic steatosis on autoimmune liver disease: A systematic review and meta-analysis
Background: The clinical impact of hepatic steatosis (HS) among patients with autoimmune liver disease (AILD) remains unclear. We aim to determine the prevalence of HS and its clinical impact on treatment response and outcomes in patients with AILD. Methods: We systematically searched 3 electronic databases until 17 December 2025, including all studies that reported the prevalence, clinical impact, and treatment response of AILD patients with concomitant HS. The temporal trend of HS prevalence was analyzed using a quasi-Poisson regression model, with annual percent changes (APC, %) calculated. Results: Overall, 44 studies, comprising 19,898 patients with autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) were included. The pooled prevalence of HS in patients with AIH, PBC, and PSC was 27.3%, 32.9%, and 21.6%, respectively. HS prevalence has significantly increased among PBC patients since 2010 (APC: +37.4%). While concomitant HS was associated with a higher risk of hepatic decompensation (OR: 1.6, 95% CI: 1.3–2.1, I 2 =0%) and hepatocellular carcinoma (OR: 1.8, 95% CI: 1.3–2.6, I 2 =0%) in patients with AIH, HS did not influence the clinical outcomes in patients with PBC. Treatment response in AIH and PBC was not influenced by concomitant HS. Available data on PSC with concomitant HS were insufficient to assess its association with clinical outcomes. Conclusions: AIH patients with concomitant HS had worse outcomes than those without HS; whereas HS did not influence the clinical outcomes in patients with PBC. Future research evaluating the impact of HS on PSC and overlap syndrome is much needed.